{"disease":{"id":"pulmonary-arterial-hypertension","name":"Pulmonary Arterial Hypertension (PAH)","therapeutic_area":"Cardiovascular","data":{"aiSummary":"The treatment landscape for PAH has evolved significantly, with the introduction of targeted therapies that improve hemodynamics and clinical outcomes. Current treatment strategies often involve combination therapy with ERAs, PDE5 inhibitors, and prostacyclin pathway agonists. Recent advances include the approval of selexipag and the promising results with sotatercept, which targets the activin signaling pathway. The pipeline includes inhaled and oral agents with novel mechanisms of action, aiming to further improve patient outcomes and quality of life.","drug_count":8,"description":"Pulmonary Arterial Hypertension (PAH) is a progressive and life-threatening condition characterized by elevated blood pressure in the pulmonary arteries, leading to right heart failure and premature death. PAH is caused by a variety of factors, including idiopathic causes, heritable conditions, and associated diseases. The current treatment landscape focuses on vasodilators and other targeted therapies to reduce pulmonary artery pressure and improve patient outcomes.","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.961Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"treprostinil","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remodulin","generic_name":"TREPROSTINIL","company_name":"United Therap","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":69,"revenue":"2000","mechanism":"Remodulin works by activating the prostacyclin receptor, which causes blood vessels to relax and widen."},{"drug_id":"sotatercept","indication_name":"pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winrevair","generic_name":"SOTATERCEPT","company_name":"Merck Sharp Dohme","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":"1443","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension."},{"drug_id":"sotatercept","indication_name":"pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winrevair","generic_name":"SOTATERCEPT","company_name":"Merck Sharp Dohme","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":"1443","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension."},{"drug_id":"macitentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opsumit","generic_name":"MACITENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":75,"revenue":"1181.0","mechanism":"Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure."},{"drug_id":"adempas","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adempas","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"beraprost","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procylin","generic_name":"BERAPROST","company_name":"","drug_phase":"discontinued","molecular_target":"Prostacyclin receptor","drug_class":"beraprost","quality_score":null,"revenue":null,"mechanism":"Procylin works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow."},{"drug_id":"revatio","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revatio","generic_name":"Sildenafil Citrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase type 5 (PDE5)","drug_class":"PDE5 inhibitor","quality_score":66,"revenue":null,"mechanism":"Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels and enabling penile smooth muscle relaxation."},{"drug_id":"epoprostenol","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flolan","generic_name":"EPOPROSTENOL","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":75,"revenue":null,"mechanism":"Flolan works by binding to the prostacyclin receptor, causing blood vessels to relax and dilate."},{"drug_id":"ambrisentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Letairis","generic_name":"AMBRISENTAN","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"selexipag","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uptravi","generic_name":"SELEXIPAG","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacyclin Receptor Agonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Uptravi works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow."},{"drug_id":"riociguat","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adempas","generic_name":"RIOCIGUAT","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":80,"revenue":null,"mechanism":"Adempas works by stimulating the soluble guanylate cyclase enzyme to increase levels of cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax blood vessels."},{"drug_id":"sitaxsentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sitaxsentan","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Endothelin B receptor, Endothelin-1 receptor, Endothelin-1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ventavis","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ventavis","company_name":"Meshalkin Research Institute of Pathology of Circulation","drug_phase":"phase_2","molecular_target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sotatercept-csrk","indication_name":"Pulmonary Arterial Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"WINREVAIR","generic_name":"SOTATERCEPT-CSRK","company_name":"MERCK SHARP DOHME","drug_phase":"marketed","molecular_target":"activin A and other TGF-β superfamily ligands","drug_class":"","quality_score":46,"revenue":null,"mechanism":"Sotatercept-csrk binds to activin A and other TGF-β superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation."},{"drug_id":"sildenafil","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viagra","generic_name":"sildenafil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5","drug_class":"PDE5 inhibitor","quality_score":null,"revenue":null,"mechanism":"Selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels to relax smooth muscle in the corpus cavernosum and pulmonary vasculature."},{"drug_id":"bosentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tracleer","generic_name":"BOSENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"prostacyclin","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prostacyclin","company_name":"United Therapeutics","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"ilomedin","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ilomedin","company_name":"Prim PD Dr Afshin Assadian","drug_phase":"phase_2","molecular_target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01347216","title":"COMPERA / COMPERA-KIDS","phase":"","overall_status":"RECRUITING","enrollment_count":14000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT05039086","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5","phase":"","overall_status":"COMPLETED","enrollment_count":13021,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT06476470","title":"Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT06954727","title":"China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT07217522","title":"Rutgers University Study of the Genetics of Pulmonary Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT07082933","title":"Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT03959748","title":"DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Polish Cardiology Association","has_results":false},{"nct_id":"NCT02126943","title":"OPsumit USers Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2686,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT06784687","title":"Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease","phase":"","overall_status":"COMPLETED","enrollment_count":2376,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03197688","title":"Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":2200,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT04930289","title":"Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Paragonix Technologies","has_results":false},{"nct_id":"NCT05566002","title":"Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Chinese Pulmonary Vascular Disease Research Group","has_results":false},{"nct_id":"NCT07164157","title":"The Risk of Adverse Pregnancy Outcomes for Long-term Exposure to Air Pollution in Pregnant Patients With Pulmonary Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Wei Huang","has_results":false},{"nct_id":"NCT01106014","title":"Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1156,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT03364244","title":"Revatio Special Investigation for Long-term Use in Pediatric Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"Viatris Pharmaceuticals Japan Inc","has_results":false},{"nct_id":"NCT05368467","title":"National Registry and Cohort Study of Pulmonary Vascular Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT03051763","title":"The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT04273945","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":935,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT01027949","title":"An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":894,"lead_sponsor_name":"United Therapeutics","has_results":true},{"nct_id":"NCT07218029","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":815,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03278002","title":"A Registry for Patients Taking Uptravi","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT01389206","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","phase":"","overall_status":"COMPLETED","enrollment_count":797,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT01112306","title":"ACT-293987 in Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01560624","title":"Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":690,"lead_sponsor_name":"United Therapeutics","has_results":true},{"nct_id":"NCT03626688","title":"A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":687,"lead_sponsor_name":"United Therapeutics","has_results":false},{"nct_id":"NCT01208792","title":"Auto-immunity and Pulmonary Arterial Hypertension","phase":"NA","overall_status":"COMPLETED","enrollment_count":629,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT00667823","title":"Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT05977933","title":"Assessing the Utility of Submaximal CPET in Treatment Management of PAH","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Shape Medical Systems, Inc.","has_results":false},{"nct_id":"NCT04677608","title":"Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"iPHNET (italian Pulmonary Hypertension NETwork)","has_results":false},{"nct_id":"NCT03954405","title":"Multi-marker Approach for Risk Assessment in PAH","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Wuhan Asia Heart Hospital","has_results":false},{"nct_id":"NCT04813926","title":"A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03977428","title":"Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Wuhan Asia Heart Hospital","has_results":false},{"nct_id":"NCT03933579","title":"The PAH Platform for Deep Phenotyping in Korean Subjects","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Gachon University Gil Medical Center","has_results":false},{"nct_id":"NCT01560637","title":"An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":471,"lead_sponsor_name":"United Therapeutics","has_results":true},{"nct_id":"NCT04972656","title":"Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension","phase":"NA","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT06987097","title":"Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":410,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT05934526","title":"Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"GB002, Inc.","has_results":false},{"nct_id":"NCT02060487","title":"Effects of Oral Sildenafil on Mortality in Adults With PAH","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":385,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT04130243","title":"Biomarkers in Pediatric Congenital Heart Disease and PAH","phase":"","overall_status":"UNKNOWN","enrollment_count":380,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04567602","title":"A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag","phase":"","overall_status":"COMPLETED","enrollment_count":372,"lead_sponsor_name":"Janssen-Cilag S.p.A.","has_results":false},{"nct_id":"NCT07481981","title":"A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":344,"lead_sponsor_name":"Insmed Incorporated","has_results":false},{"nct_id":"NCT04576988","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","has_results":true},{"nct_id":"NCT04811092","title":"Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","has_results":false},{"nct_id":"NCT00367523","title":"Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria","phase":"","overall_status":"COMPLETED","enrollment_count":308,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04808596","title":"Pulmonary Hypertension Biorepository and Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT01841762","title":"Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01908699","title":"Beraprost-314d Added-on to Tyvaso® (BEAT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"Lung Biotechnology PBC","has_results":true},{"nct_id":"NCT06683040","title":"Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","has_results":false},{"nct_id":"NCT05417373","title":"Algorithms to Diagnose Pulmonary Arterial Hypertension","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"RenJi Hospital","has_results":false}],"total":50},"guidelines":[{"drug_id":"revatio","guideline_body":"FDA label","recommendation":"Sildenafil is indicated for the treatment of pulmonary arterial hypertension.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"viagra","guideline_body":"FDA label","recommendation":"Sildenafil is indicated for the treatment of pulmonary arterial hypertension.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}